Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database

OBJECTIVE: Randomized controlled trials have shown kidney-protective effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested that these effects translate to clinical practice. However, long-term efficacy, as well as whether the presence or absence...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagasu, Hajime, Yano, Yuichiro, Kanegae, Hiroshi, Heerspink, Hiddo J.L., Nangaku, Masaomi, Hirakawa, Yosuke, Sugawara, Yuka, Nakagawa, Naoki, Tani, Yuji, Wada, Jun, Sugiyama, Hitoshi, Tsuruya, Kazuhiko, Nakano, Toshiaki, Maruyama, Shoichi, Wada, Takashi, Yamagata, Kunihiro, Narita, Ichiei, Tamura, Kouichi, Yanagita, Motoko, Terada, Yoshio, Shigematsu, Takashi, Sofue, Tadashi, Ito, Takafumi, Okada, Hirokazu, Nakashima, Naoki, Kataoka, Hiromi, Ohe, Kazuhiko, Okada, Mihoko, Itano, Seiji, Nishiyama, Akira, Kanda, Eiichiro, Ueki, Kohjiro, Kashihara, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2021
Materias:
Emerging Therapies: Drugs and Regimens
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546274/
https://www.ncbi.nlm.nih.gov/pubmed/34593566
http://dx.doi.org/10.2337/dc21-1081

Ejemplares similares

Ejemplares similares